Globally defining the effects of mutations in a picornavirus capsid.
Deep mutational scanning
capsid
evolutionary biology
human
infectious disease
microbiology
mutational fitness effects
picornavirus
viral protease
virus
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
12 01 2021
12 01 2021
Historique:
received:
22
10
2020
accepted:
11
01
2021
pubmed:
13
1
2021
medline:
4
2
2022
entrez:
12
1
2021
Statut:
epublish
Résumé
The capsids of non-enveloped viruses are highly multimeric and multifunctional protein assemblies that play key roles in viral biology and pathogenesis. Despite their importance, a comprehensive understanding of how mutations affect viral fitness across different structural and functional attributes of the capsid is lacking. To address this limitation, we globally define the effects of mutations across the capsid of a human picornavirus. Using this resource, we identify structural and sequence determinants that accurately predict mutational fitness effects, refine evolutionary analyses, and define the sequence specificity of key capsid-encoded motifs. Furthermore, capitalizing on the derived sequence requirements for capsid-encoded protease cleavage sites, we implement a bioinformatic approach for identifying novel host proteins targeted by viral proteases. Our findings represent the most comprehensive investigation of mutational fitness effects in a picornavirus capsid to date and illuminate important aspects of viral biology, evolution, and host interactions. A virus is made up of genetic material that is encased with a protective protein coat called the capsid. The capsid also helps the virus to infect host cells by binding to the host receptor proteins and releasing its genetic material. Inside the cell, the virus hitchhikes the infected cell’s machinery to grow or replicate its own genetic material. Viral capsids are the main target of the host’s defence system, and therefore, continuously change in an attempt to escape the immune system by introducing alterations (known as mutations) into the genes encoding viral capsid proteins. Mutations occur randomly, and so while some changes to the viral capsid might confer an advantage, others may have no effect at all, or even weaken the virus. To better understand the effect of capsid mutations on the virus’ ability to infect host cells, Mattenberger et al. studied the Coxsackievirus B3, which is linked to heart problems and acute heart failure in humans. The researchers analysed around 90% of possible amino acid mutations (over 14,800 mutations) and correlated each mutation to how it influenced the virus’ ability to replicate in human cells grown in the laboratory. Based on these results, Mattenberger et al. developed a computer model to predict how a particular mutation might affect the virus. The analysis also identified specific amino acid sequences of capsid proteins that are essential for certain tasks, such as building the capsid. It also included an analysis of sequences in the capsid that allow it to be recognized by another viral protein, which cuts the capsid proteins into the right size from a larger precursor. By looking for similar sequences in human genes, the researchers identified several ones that the virus may attack and inactivate to support its own replication. These findings may help identify potential drug targets to develop new antiviral therapies. For example, proteins of the capsid that are less likely to mutate will provide a better target as they lower the possibility of the virus to become resistant to the treatment. They also highlight new proteins in human cells that could potentially block the virus in cells.
Autres résumés
Type: plain-language-summary
(eng)
A virus is made up of genetic material that is encased with a protective protein coat called the capsid. The capsid also helps the virus to infect host cells by binding to the host receptor proteins and releasing its genetic material. Inside the cell, the virus hitchhikes the infected cell’s machinery to grow or replicate its own genetic material. Viral capsids are the main target of the host’s defence system, and therefore, continuously change in an attempt to escape the immune system by introducing alterations (known as mutations) into the genes encoding viral capsid proteins. Mutations occur randomly, and so while some changes to the viral capsid might confer an advantage, others may have no effect at all, or even weaken the virus. To better understand the effect of capsid mutations on the virus’ ability to infect host cells, Mattenberger et al. studied the Coxsackievirus B3, which is linked to heart problems and acute heart failure in humans. The researchers analysed around 90% of possible amino acid mutations (over 14,800 mutations) and correlated each mutation to how it influenced the virus’ ability to replicate in human cells grown in the laboratory. Based on these results, Mattenberger et al. developed a computer model to predict how a particular mutation might affect the virus. The analysis also identified specific amino acid sequences of capsid proteins that are essential for certain tasks, such as building the capsid. It also included an analysis of sequences in the capsid that allow it to be recognized by another viral protein, which cuts the capsid proteins into the right size from a larger precursor. By looking for similar sequences in human genes, the researchers identified several ones that the virus may attack and inactivate to support its own replication. These findings may help identify potential drug targets to develop new antiviral therapies. For example, proteins of the capsid that are less likely to mutate will provide a better target as they lower the possibility of the virus to become resistant to the treatment. They also highlight new proteins in human cells that could potentially block the virus in cells.
Identifiants
pubmed: 33432927
doi: 10.7554/eLife.64256
pii: 64256
pmc: PMC7861617
doi:
pii:
Substances chimiques
Capsid Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2021, Mattenberger et al.
Déclaration de conflit d'intérêts
FM, VL, OT, AS, RG No competing interests declared
Références
Proteomics. 2004 Jun;4(6):1626-32
pubmed: 15174132
Trends Microbiol. 2002 Jul;10(7):324-31
pubmed: 12110211
J Virol. 2012 Dec;86(23):12571-81
pubmed: 22973031
BMC Bioinformatics. 2015 May 20;16:168
pubmed: 25990960
Annu Rev Phys Chem. 2015 Apr;66:217-39
pubmed: 25532951
Cell Syst. 2018 Jan 24;6(1):116-124.e3
pubmed: 29226803
Nat Biotechnol. 2004 Oct;22(10):1302-6
pubmed: 15361882
Microbiol Mol Biol Rev. 2014 Sep;78(3):418-37
pubmed: 25184560
J Virol. 1992 Mar;66(3):1520-7
pubmed: 1310763
Nucleic Acids Res. 2012 Jan;40(Database issue):D593-8
pubmed: 22006842
Nat Commun. 2018 Apr 11;9(1):1385
pubmed: 29643335
J Virol. 2015 Jan 15;89(2):1242-53
pubmed: 25392218
Elife. 2019 Aug 27;8:
pubmed: 31452511
PLoS Pathog. 2016 Dec 13;12(12):e1006114
pubmed: 27959955
Cell Rep. 2019 Oct 15;29(3):714-723.e4
pubmed: 31618638
Cell Rep. 2019 May 14;27(7):2157-2170.e8
pubmed: 31091453
Nat Microbiol. 2017 Jun 05;2:17088
pubmed: 28581455
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W382-8
pubmed: 15980494
Annu Rev Phytopathol. 2001;39:419-60
pubmed: 11701872
PLoS Genet. 2015 Jul 01;11(7):e1005310
pubmed: 26132554
Genes Dev. 2014 Nov 1;28(21):2370-80
pubmed: 25301780
Rev Med Virol. 2016 Jul;26(4):251-67
pubmed: 27145174
Biol Direct. 2017 Jan 17;12(1):1
pubmed: 28095902
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
Mol Syst Biol. 2020 Jul;16(7):e9380
pubmed: 32627955
FEBS Lett. 2015 Jan 2;589(1):3-14
pubmed: 25479087
Elife. 2018 Mar 28;7:
pubmed: 29590010
Viruses. 2016 Mar 17;8(3):82
pubmed: 26999188
Nucleic Acids Res. 2018 Jul 2;46(W1):W235-W241
pubmed: 29873773
Elife. 2014 Jul 08;3:
pubmed: 25006036
PLoS Pathog. 2017 Mar 27;13(3):e1006288
pubmed: 28346537
Nature. 2014 Jan 30;505(7485):686-90
pubmed: 24284629
EMBO J. 2000 Mar 15;19(6):1207-16
pubmed: 10716921
mBio. 2016 Nov 1;7(6):
pubmed: 27803181
Nat Commun. 2017 Sep 11;8(1):505
pubmed: 28894095
PLoS Pathog. 2014 Apr 10;10(4):e1004039
pubmed: 24722756
Science. 2019 Nov 29;366(6469):1139-1143
pubmed: 31780559
Viruses. 2016 Jun 03;8(6):
pubmed: 27271655
PLoS Pathog. 2018 Aug 6;14(8):e1007203
pubmed: 30080883
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14508-13
pubmed: 22853953
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
J Virol Methods. 2007 Feb;139(2):181-8
pubmed: 17092574
Nucleic Acids Res. 2009 Jan;37(Database issue):D436-42
pubmed: 18981051
J Virol. 2018 Mar 28;92(8):
pubmed: 29437971
PeerJ. 2017 Jul 31;5:e3657
pubmed: 28785526
Virology. 1988 Sep;166(1):265-70
pubmed: 2842953
J Virol. 2019 Jun 14;93(13):
pubmed: 31019050
Genes Dev. 2007 Jan 15;21(2):195-205
pubmed: 17234885
Front Cell Infect Microbiol. 2019 Aug 20;9:283
pubmed: 31482072
Cell. 2009 Dec 24;139(7):1243-54
pubmed: 20064371
Mol Biol Evol. 2014 Aug;31(8):1956-78
pubmed: 24859245
Bioinformatics. 2015 Jan 1;31(1):94-101
pubmed: 25178459
Bioinformatics. 2016 Jul 1;32(13):2029-31
pubmed: 27153727
J Med Chem. 1999 Apr 8;42(7):1213-24
pubmed: 10197965
PLoS Pathog. 2014 Oct 02;10(10):e1004422
pubmed: 25275585
Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):73-8
pubmed: 10618373
Cell Host Microbe. 2017 Jun 14;21(6):777-787.e4
pubmed: 28579254
Structure. 1995 Jul 15;3(7):653-67
pubmed: 8591043
Nat Protoc. 2014 Nov;9(11):2586-606
pubmed: 25299156
BMC Bioinformatics. 2018 Dec 10;19(1):473
pubmed: 30526486
PLoS Pathog. 2019 Jan 18;15(1):e1007509
pubmed: 30657784
BMC Genomics. 2015;16 Suppl 8:S1
pubmed: 26110438
BMC Bioinformatics. 2020 Mar 17;21(1):107
pubmed: 32183714